Recent Updates
Recently added Catalysts

APL-3007, pegcetacoplan

Phase 2

Geographic Atrophy Secondary to Age-related Macular Degeneration | Small molecule | Ophthalmology |Apellis Pharmaceuticals, Inc.|Last Updated: Jun 24, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment240
FDA Designations
No designations recorded
Clinical trial landscape

APL-3007, pegcetacoplan · 1 trial · 1 indication

Phase 2 1
NCT07215390A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular DegeneratioGeographic Atrophy Secondary to Age-related Macular Degeneration
RECRUITING240 Analytics
PHASE2RECRUITING
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07215390240
Unlock trial analytics
Study Endpoints
Primary Endpoints
Change from baseline (CFB) in the area of artificial intelligence (AI)-based SD-OCT assessment of RPE lesion in the study eye
At month 12
Secondary Endpoints
CFB in the area of AI-based OCT assessment of photoreceptor degeneration in the study eye
At month 12
Safety & tolerability based on adverse event (AE) reporting
At month 12
Safety as assessed by Best Corrected Visual Acuity (BCVA)
At Month 12
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Group 1 (APL-3007 Dose/Frequency 1 )EXPERIMENTALAPL-3007 SC + pegcetacoplan (APL-2)
Group 2 (APL-3007 Dose/Frequency 2)EXPERIMENTALAPL-3007 + pegcetacoplan (APL-2)
Group 3 (placebo)PLACEBO_COMPARATORPlacebo SC + pegcetacoplan (APL-2)
Interventions
NameTypeDescription
APL-3007, pegcetacoplan (APL-2)DRUGComplement C3 inhibitor
Placebo, SyfovreOTHERComplement C3 Inhibitor
Unlock Study Design Details
Eligibility Criteria
Age Range60 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites78

Inclusion Criteria: * The study eye must meet all inclusion criteria. If both eyes meet the inclusion criteria, the eye with better normal luminance visual acuity at the screening visit will be designated as the study eye. If both eyes have the same visual acuity, the right eye will be used as the ...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJun 24, 2026NCT07215390primaryCompletionDate: changed
LOWJun 24, 2026NCT07215390primaryCompletionDate: changed
MEDIUMJun 22, 2026NCT07215390primaryCompletionDate: changed
MEDIUMJun 22, 2026NCT07215390primaryCompletionDate: changed
LOWJun 4, 2026NCT07215390lastUpdatePostDate: changed
LOWJun 4, 2026NCT07215390lastUpdatePostDate: changed
LOWJun 4, 2026NCT07215390lastUpdatePostDate: changed
LOWJun 4, 2026NCT07215390lastUpdatePostDate: changed
LOWMay 26, 2026NCT07215390primaryCompletionDate: changed
LOWMay 24, 2026NCT07215390studyFirstPostDate: changed